Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
OBJECTIVE
We examined the role of paclitaxel and cisplatin as first line therapy for metastatic urothelial cancer.


METHODS
A total of 34 patients were enrolled in this study, and all were eligible for treatment and assessable for response. Patients received 135 mg./m.2 paclitaxel intravenously for 3 hours followed by 70 mg./m.2 cisplatin for 2 hours every 3 weeks to a maximum of 6 cycles.


RESULTS
Of the patients 70% experienced a major response to treatment, which was partial/regression in 38% and complete in 32%. Toxicity was manageable with no episodes of grade 4 leukopenia or thrombocytopenia. Nonhematological toxicities included primarily nausea, anorexia and neuropathy, which rarely were severe.


CONCLUSIONS
This regimen of paclitaxel and cisplatin is effective, safe and convenient to administer in an outpatient setting for advanced urothelial cancer.
Burch
P A
PA
Division of Medical Oncology, Department of Biostatistics, Mayo Foundation, Rochester, Minnesota, USA.
Richardson
R L
RL
Cha
S S
SS
Sargent
D J
DJ
Pitot
H C
HC
Kaur
J S
JS
Camoriano
J K
JK
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D014516:Ureteral Neoplasms / Q000188:drug therapy* / Q000401:mortality; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality
D017239:Paclitaxel; D002945:Cisplatin